THE RISK OF ACUTE MYOCARDIAL-INFARCTION AFTER ESTROGEN AND ESTROGEN PROGESTOGEN REPLACEMENT

被引:306
作者
FALKEBORN, M
PERSSON, I
ADAMI, HO
BERGSTROM, R
EAKER, E
LITHELL, H
MOHSEN, R
NAESSEN, T
机构
[1] UNIV HOSP UPPSALA,DEPT OBSTET & GYNAECOL,UPPSALA,SWEDEN
[2] UNIV HOSP UPPSALA,CANC EPIDEMIOL UNIT,UPPSALA,SWEDEN
[3] UNIV UPPSALA,DEPT STAT,S-75105 UPPSALA,SWEDEN
[4] CTR DIS CONTROL,ATLANTA,GA 30333
[5] UNIV UPPSALA,DEPT GERIATR,S-75105 UPPSALA,SWEDEN
[6] UNIV UPPSALA,DEPT OBSTET & GYNAECOL,S-75105 UPPSALA,SWEDEN
来源
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY | 1992年 / 99卷 / 10期
关键词
D O I
10.1111/j.1471-0528.1992.tb14414.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To determine the relative risk of developing a first acute myocardial infarction after treatment with oestrogens alone or oestrogen-progestogen combinations. Design Prospective cohort study utilizing a prescription-based and record linkage system for a follow-up period from 1977 to 1983. Average individual observation time was 5-8 years. Setting The entire female population of the Uppsala Health Care Region (1-4 million inhabitants), one-sixth of the total Swedish population. Subjects 23 174 women aged 35 years and older, identified from pharmacy records as having been prescribed non-contraceptive oestrogens during 1977-1980. Outcomes Admissions to hospitals for first acute myocardial infarctions. Results Overall, 227 cases of a first acute myocardial infarction were observed as against 281.1 expected, RR=0.81 (95 % confidence limits 0.71 to 0.92). Women who were younger than 60 years at entry into the study and prescribed oestradiol compounds (1-2 mg) or conjugated oestrogens (0.625-1.25 mg) showed a significant 30% reduction of the relative risk (RR=0.69, 0.54 to 0.86). Those prescribed a combined oestradiol-levonorgestrel brand also demonstrated a significantly lowered relative risk (RR=0.53, 0.30 to 0.87). The risk estimates were near unity during the first year of follow-up but decreased during subsequent years. Exposure to the weak oestrogen oestriol did not after the risk. Conclusion Hormonal replacement therapy with oestrogens alone, and maybe also when cyclically combined with progestogens, can reduce the risk of acute myocardial infarction.
引用
收藏
页码:821 / 828
页数:8
相关论文
共 42 条
[1]  
AVILA MH, 1990, EPIDEMIOLOGY, V1, P128
[2]   ESTROGEN AND CORONARY HEART-DISEASE IN WOMEN [J].
BARRETTCONNOR, E ;
BUSH, TL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (14) :1861-1867
[3]   RISK-FACTORS FOR BREAST AND ENDOMETRIAL CANCER IN A COHORT OF WOMEN TREATED WITH MENOPAUSAL ESTROGENS [J].
BERGKVIST, L ;
PERSSON, I ;
ADAMI, HO ;
SCHAIRER, C .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1988, 17 (04) :732-737
[4]   THE RISK OF BREAST-CANCER AFTER ESTROGEN AND ESTROGEN PROGESTIN REPLACEMENT [J].
BERGKVIST, L ;
ADAMI, HO ;
PERSSON, I ;
HOOVER, R ;
SCHAIRER, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (05) :293-297
[5]   A METAANALYSIS OF PHYSICAL-ACTIVITY IN THE PREVENTION OF CORONARY HEART-DISEASE [J].
BERLIN, JA ;
COLDITZ, GA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1990, 132 (04) :612-628
[6]   MULTIPLICATIVE MODELS AND COHORT ANALYSIS [J].
BRESLOW, NE ;
LUBIN, JH ;
MAREK, P ;
LANGHOLZ, B .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1983, 78 (381) :1-12
[7]   NONCONTRACEPTIVE ESTROGEN USE AND CARDIOVASCULAR-DISEASE [J].
BUSH, TL ;
BARRETTCONNOR, E .
EPIDEMIOLOGIC REVIEWS, 1985, 7 :80-104
[8]   CARDIOVASCULAR MORTALITY AND NONCONTRACEPTIVE USE OF ESTROGEN IN WOMEN - RESULTS FROM THE LIPID RESEARCH CLINICS PROGRAM FOLLOW-UP-STUDY [J].
BUSH, TL ;
BARRETTCONNOR, E ;
COWAN, LD ;
CRIQUI, MH ;
WALLACE, RB ;
SUCHINDRAN, CM ;
TYROLER, HA ;
RIFKIND, BM .
CIRCULATION, 1987, 75 (06) :1102-1109
[9]  
COPLAND KT, 1977, AM J EPIDEMIOL, V105, P488
[10]   POSTMENOPAUSAL ESTROGEN USE AND MORTALITY - RESULTS FROM A PROSPECTIVE-STUDY IN A DEFINED, HOMOGENEOUS COMMUNITY [J].
CRIQUI, MH ;
SUAREZ, L ;
BARRETTCONNOR, E ;
MCPHILLIPS, J ;
WINGARD, DL ;
GARLAND, C .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1988, 128 (03) :606-614